Binx Health IO CT/NG Assay: The World's First 30-Minute Molecular Point-of-Care Test for Chlamydia and Gonorrhea

David Pearce1, Charlotte Gaydos2

  • 1binx health
  • 2Johns Hopkins University


12:30 - 14:30 | Thu 21 November | Room E1&2 | B1P-A.5

Session: [B1P-A] Technology Demonstrations

Category: Poster Session
Theme: Technology Demonstration Showcase

Full Text


The binx io Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Assay running on the binx io platform is designed to reduce the time taken between testing for CT and NG and treating appropriately from days and weeks to minutes – enabling a ‘test and treat’ approach for the first time. The io was recently cleared by the FDA for use in point-of-care or clinical laboratory settings for the detection of CT and NG in female vaginal swab samples following a validation study that demonstrated a 96.1% sensitivity and 99.1% specificity for CT and 100% sensitivity and 99.9% specificity for NG.